• Skip to main content
  • Skip to footer
Dicerna Pharmaceuticals

Nổ hũ đổi thưởng uy tínDicerna Pharmaceuticals

Dicerna

  • Careers at Dicerna
  • News
  • Contact
  • Our
    Company
    • Management Team
    • Board of
      Directors
    • Collaborating
    • Intellectual Property
    • Grants & Charitable Donations
  • Our GalXC™ Technology
    • Scientific Publications
  • Pipeline
    • Nedosiran (formerly DCR-PHXC)
    • RG6346 (formerly DCR-HBVS)
    • DCR-A1AT
    • Collaborative Programs
    • Clinical Trials
  • Patients
    • A Message To Our Patients
    • Patient Advocacy Charter
    • Primary Hyperoxaluria (PH)
    • Hepatitis B Virus
    • Alpha-1 Antitrypsin Deficiency-associated Liver Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Investor FAQs
    • Contact

Play Video

Applying RNAi to fight disease

At Dicerna, we use RNA interference, or RNAi, to create medicines that silence or turn off the genes that cause disease. Using our GalXC technology platform, we develop potent and patient-friendly RNAi therapies – in-house and with our partners – for both rare diseases and common diseases with a genetic component.

0
GaIXC programs in clinical trials
0
GaIXC programs in early-stage development
0
Major research and development collaborations

Our GalXC™ pipeline and platform

Our proprietary GalXC technologyNổ hũ đổi thưởng uy tín opens a world of possibilities for creating targeted and potent RNAi therapies. These therapies are thought to be more convenient for patients because they can be delivered under the skin and have a long duration of action.

Nổ hũ đổi thưởng uy tínWe currently have three drug candidates in clinical trials:

  • Nedosiran (DCR-PHXC): all three known types of primary hyperoxaluria (PH) 
  • RG6346 (DCR-HBVS): hepatitis B virus (HBV) infection
  • DCR-A1AT: alpha-1 antitrypsin deficiency-associated liver disease

News

Nov

16

2020

Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020

Nov

16

2020

Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement

Nov

11

2020

Dicerna to Participate in Upcoming Investor Conferences

Events & Presentations

Nov

18

2020

Stifel Virtual Healthcare Conference

Nov

20

2020

Dicerna Corporate Overview

Dec

1

2020

Evercore ISI 3rd Annual HealthCONx Virtual Conference

Our commitment to patients

We believe all patients deserve safe and effective medicines that can improve the quality and duration of their lives. Our goal is to understand and ease the unique disease-related burdens of patients and their caregivers as we create new medicines with the potential to restore their health.

Join our team

Nổ hũ đổi thưởng uy tínWe’re a company that breaks down the barriers that impede our science or your ambitions. We invite and inspire collaboration among employees, patients, physicians and industry partners throughout the process of drug discovery, development and commercialization.

video preview

Our mission

We interfere with disease

We use RNA interference, or RNAi, to create medicines that silence the genes that cause disease. Our goal is to provide life-changing therapies to people living with rare diseases and common diseases that have a genetic component.

Footer

Dicerna™

Follow us:

  • Careers at Dicerna
  • News
  • Contact

©2020 Dicerna Pharmaceuticals, Inc. | Lexington, MA
Last revised Apr. 2020

  • Our
    Company
  • Our GalXC™ Technology
  • Pipeline
  • Patients
  • Investors & Media
  • Privacy Policy
  • Cookies Policy
  • Copyright Info
  • Terms of Use
  • Site Map
  • Glossary of Key Terms
logo
  • Our
    Company
    • Management Team
    • Board of
      Directors
    • Collaborating
    • Intellectual Property
    • Grants & Charitable Donations
  • Our GalXC™ Technology
    • Scientific Publications
  • Pipeline
    • Nedosiran
      (DCR-PHXC)
    • RG6346 (formerly DCR-HBVS)
    • DCR-A1AT
    • Collaborative Programs
    • Clinical Trials
  • Patients
    • A Message To Our Patients
    • Patient Advocacy Charter
    • Primary Hyperoxaluria (PH)
    • Hepatitis B Virus
    • Alpha-1 Antitrypsin Deficiency-associated Liver Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Investor FAQs
    • Contact
  • Careers at Dicerna
  • News
  • Contact
Close

Cookies Policy

This site uses cookies as described in our Cookies Policy. To learn more about cookies, including how to disable them, view our Cookies Policy.
Click here to accept these terms.